Artiva Biotherapeutics, Inc. - 10-Q Filing
Artiva Biotherapeutics filed a Form 10-Q for the quarter ended March 31, 2025. The filing includes details on equity incentive plans, license agreements with GC Cell including AB-201 and AB-205 products, services agreements with Ra Capital Management LP and Blackbird Services Agreement, as well as financial instruments such as short-term investments in US government agencies debt securities and commercial paper.
Tickers: $ARTV